Cross-referencing clinical data
PromisingLacticaseibacillus casei HRVD300-US
Lacticaseibacillus casei HRVD300-US.
A documented L. casei strain that supports digestive balance and immune function. Supports the balance of gut bacteria, aids digestion, and helps maintain immune function. L. casei strains colonize the intestinal lining and compete with harmful bacteria for resources.
PromisingResearch strength5,000,000,000CFUDaily amount
Reviewed March 2026
- Category
- Probiotic
- Also filed under
- Digestive healthImmune modulationPathogen competitionGut barrier support
What Lacticaseibacillus casei HRVD300-US is, and what it does.
- Does it work
- L. Casei as a species has good evidence. This specific HRVD300-US strain doesn't have its own published trials, but the species-level data is reassuring. It's a solid supporting player in a multi-strain probiotic, not a standalone star.
- How much to take
- 1-10 billion CFU daily. In multi-strain formulas, individual strain counts are often lower but the synergistic effect of multiple strains can compensate. Look for products guaranteeing CFU count at expiration, not just at manufacture.
- The first dose
- Mild gas or bloating is possible as your gut adjusts to new bacteria. This usually resolves within a few days. Some people notice subtle digestive improvements right away, but most need 1-2 weeks.
- With regular use
- By week 3-4, expect more regular digestion, less post-meal bloating, and potentially fewer minor GI complaints. Some studies show reduced frequency and duration of common colds with long-term L. casei use.
- How well tolerated
- Well tolerated for healthy adults. Probiotics in general have an excellent safety record. Caution in severely immunocompromised individuals (rare risk of bacteremia). Start with lower doses if you're new to probiotics to minimize initial gas.
- How it feels
- Quieter digestion. The kind of improvement where you realize you haven't been bloated in a while, rather than a dramatic moment. Bowel movements may become more predictable. It's maintenance-level improvement.
About 5,000,000,000 CFU a day is the studied dose.
How much to take a dayMedium confidence
Up to 1,000,000,000 CFUA supporting amount. Helps a little, not the studied dose.
1,000,000,000 CFU to 5,000,000,000 CFUEnough for most people, and where a lot of good products land.
5,000,000,000 CFU
The doseThe daily amount the trials actually used. A product at this figure is dosed right where the research is.
Above 5,000,000,000 CFUMore capsules, not more effect. Rarely in a serving anyway.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
- Improves digestive health
- Supports immune function
- This specific HRVD300-US strain has unique benefits
PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.PubMedCochraneClinicalTrials.govNIH ODSSUPP.AILabs test. IngredientMD verifies.
Questions people ask about Lacticaseibacillus casei HRVD300-US.
- What does the HRVD300-US designation mean?
- HRVD likely stands for a Harvard-affiliated digestive culture collection. The 300-US is the specific strain identifier. It means this is a documented, deposited strain, not a random isolate. That said, strain-specific published studies are limited.
- Should I take it with or without antibiotics?
- Both. Take your probiotic 2 hours away from your antibiotic dose (so the antibiotic doesn't immediately kill the probiotic). Continue for at least 2 weeks after finishing antibiotics to help restore gut flora.
- Do I need to refrigerate it?
- Depends on the product. Some use shelf-stable technology (like freeze-drying with protective matrices). Check your specific product's storage instructions. When in doubt, refrigeration extends viability.
- How is this different from L. casei Shirota (in Yakult)?
- Different strains of the same species. L. casei Shirota has decades of specific research behind it. HRVD300-US has the species-level evidence but less strain-specific data. Both should provide core L. casei benefits.
- Can I take too many probiotics?
- Unlikely to cause harm, but more isn't always better. Above 20-50 billion CFU total (across all strains), you're probably not getting additional benefit and may get more gas. Stick to recommended doses.
- Will it survive stomach acid?
- Some bacteria die in stomach acid, yes. That's why enteric-coated or delayed-release capsules help. Taking with food also buffers the acid. Quality products account for acid loss by including extra CFU.
Nothing to show here, and the reason why.
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Lacticaseibacillus casei HRVD300-US has none that clears that bar.
No pairing for Lacticaseibacillus casei HRVD300-US has cleared review yet.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
Plays well withEstablished knowledge, not a trial
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Lacticaseibacillus casei HRVD300-US + inulinInulin is a fermentable fructan that lactobacilli can use as a growth substrate.
Lacticaseibacillus casei carries the enzymes to use fructan-derived fructose once inulin is broken down in the gut environment. Pairing a live culture with a substrate it can use is the basic synbiotic logic. Whether a specific strain benefits depends on its own carbohydrate utilisation profile, which is strain-level information the manufacturer holds.
Lacticaseibacillus casei HRVD300-US + fos-fructooligosaccharidesShort-chain fructans are among the most readily used substrates for lactobacilli.
FOS has a shorter chain length than inulin and is fermented earlier in the colon, closer to where an ingested culture first arrives. Lactobacilli commonly carry beta-fructofuranosidase activity to access it. The pairing is standard synbiotic construction.
Lacticaseibacillus casei HRVD300-US + gos-galactooligosaccharidesGOS is fermented by lactobacilli and bifidobacteria and is a conventional synbiotic partner.
Galactooligosaccharides resist human digestion and are used by beta-galactosidase-carrying lactic acid bacteria. L. casei is a beta-galactosidase producer, which is also why the species is used in dairy fermentation. Co-formulating gives the delivered organisms something to work on.
Lacticaseibacillus casei HRVD300-US + resistant-starchResistant starch feeds colonic fermentation but is used by different primary degraders than fructans.
Starch degraders such as Ruminococcus and Bifidobacterium open resistant starch granules, releasing oligosaccharides that cross-feeding organisms including lactobacilli can use. The benefit to a delivered Lacticaseibacillus is indirect, through that cross-feeding chain. It broadens the fermentable substrate pool rather than feeding the strain directly.
Lacticaseibacillus casei HRVD300-US + partially-hydrolyzed-guar-gumA gently fermented soluble fibre that supports colonic fermentation with lower gas production than fructans.
Partially hydrolysed guar gum ferments slowly and more distally than FOS, spreading substrate availability along the bowel. It is used in synbiotic formats where fructan tolerance is a concern. Read the pairing as substrate provision rather than a strain-specific finding.
Lacticaseibacillus casei HRVD300-US + bifidobacterium-lactisMulti-strain formulas pair lactobacilli and bifidobacteria for coverage of different gut compartments.
Bifidobacteria dominate the proximal colon and lactobacilli are more associated with the small intestine and mucosal surfaces. Combining genera addresses different niches rather than doubling one. Effects are strain-specific and do not transfer between combinations.
Lacticaseibacillus casei HRVD300-US + bifidobacterium-longumA commonly co-formulated bifidobacterium occupying a different niche from lactobacilli.
B. longum ferments a wider range of complex carbohydrates than most lactobacilli and produces acetate and lactate that other organisms use. Co-formulation targets breadth of colonisation. Any combined effect must be measured for the specific pair, not inferred.
Lacticaseibacillus casei HRVD300-US + lactobacillus-plantarumAnother lactic acid bacterium routinely blended with L. casei strains.
L. plantarum has a broad carbohydrate utilisation range and tolerates acid and bile well, which is why it survives transit. Blending it with a casei strain widens the metabolic range of what is delivered. Neither displaces the other in a multi-strain product at typical ratios.
Lacticaseibacillus casei HRVD300-US + lactobacillus-acidophilusBoth are acid-producing lactobacilli used together in conventional multi-strain formats.
Acidophilus and casei strains both generate lactic acid, lowering local luminal pH. Their bile tolerance and adhesion profiles differ, so they occupy overlapping but not identical positions. This is standard multi-strain construction.
Lacticaseibacillus casei HRVD300-US + saccharomyces-boulardiiA yeast that is unaffected by the conditions that limit bacterial cultures.
S. boulardii is a yeast and does not share the bacterial cell-wall targets that antibacterial agents act on, so it persists where bacterial cultures do not. Pairing it with a Lacticaseibacillus gives two organisms with different vulnerabilities. The rationale is coverage, not a demonstrated combined effect.
Lacticaseibacillus casei HRVD300-US + butyrateButyrate is a downstream product of the cross-feeding chain that lactate-producing bacteria start.
Lactic acid bacteria produce lactate, which butyrate producers such as Anaerostipes and Eubacterium convert onward to butyrate. Supplying butyrate directly and supplying an organism that feeds its producers are two routes to the same end product. Colonocytes use butyrate as their preferred fuel.
Lacticaseibacillus casei HRVD300-US + lactaseL. casei carries beta-galactosidase activity, which is the same enzymatic function a lactase supplement provides.
Lacticaseibacillus casei is a dairy fermentation organism with beta-galactosidase, the enzyme that cleaves lactose into glucose and galactose. A lactase supplement supplies that activity directly in the small intestine. Both address the same bond, at different points and by different means.
Lacticaseibacillus casei HRVD300-US + colostrum-bovineColostrum supplies oligosaccharides and immunoglobulins alongside a live culture.
Bovine colostrum carries milk oligosaccharides that resist digestion and reach the colon, plus immunoglobulin fractions. The oligosaccharide component gives delivered organisms a substrate. The combination is a formulation approach rather than a measured pairing for this strain.
Lacticaseibacillus casei HRVD300-US + lactoferrinLactoferrin sequesters iron, which shapes which gut organisms can grow.
Lactoferrin binds free iron tightly, limiting availability to iron-requiring organisms. Most lactobacilli have a low or absent iron requirement, which is why they are relatively unaffected. The result is a selective pressure in the lumen rather than a direct effect on the delivered strain.
Lacticaseibacillus casei HRVD300-US + zinc-carnosineBoth are used in formulas addressing normal gut lining function, by unrelated routes.
Zinc carnosine is a chelate studied for mucosal integrity; a live culture acts through colonisation, acid production and competitive exclusion. Their mechanisms do not overlap or interfere. The pairing is formulation convention.
Lacticaseibacillus casei HRVD300-US + l-glutamineGlutamine is the primary fuel for enterocytes and is combined with cultures in gut formulas.
Enterocytes of the small intestine oxidise glutamine preferentially, while colonocytes prefer butyrate. A live culture acts on the luminal side and glutamine on the cell's substrate supply. The two are independent inputs combined by formulation practice.
Lacticaseibacillus casei HRVD300-US + psyllium-huskPsyllium is a gel-forming fibre that is only partially fermented.
Psyllium's main action is viscosity and stool bulking rather than rapid fermentation, so it adds bulk without the gas load of a fructan. A modest fermentable fraction still reaches colonic bacteria. Pairing it with a culture separates the bulking and microbial functions.
Lacticaseibacillus casei HRVD300-US + beta-glucan-oatOat beta-glucan is a viscous soluble fibre fermented in the colon.
Beta-1,3/1,4-glucan from oats resists human digestion and is fermented by colonic bacteria to short-chain fatty acids. It supplies substrate that a delivered culture and the resident community can both draw on. Viscosity also slows transit, which changes contact time.
Lacticaseibacillus casei HRVD300-US + activated-charcoalActivated charcoal adsorbs a wide range of luminal contents non-selectively.
Charcoal binds organic molecules indiscriminately in the gut lumen, including the nutrients and metabolites a delivered culture depends on. It also physically adsorbs bacterial cells. Anyone taking both should separate the doses by several hours.
Lacticaseibacillus casei HRVD300-US + bentonite-clayBinding clays adsorb luminal contents and delivered organisms alike.
Bentonite has a high surface charge and binds a broad range of molecules and particles in the gut. Live cultures taken at the same time are exposed to that binding. Timing separation is the practical answer rather than avoidance of either.
Lacticaseibacillus casei HRVD300-US + oregano-oilOregano oil phenolics are broadly antimicrobial and do not spare lactic acid bacteria.
Carvacrol and thymol disrupt bacterial membranes without distinguishing between resident, delivered and unwanted organisms. Taking an antimicrobial botanical alongside a live culture works against the culture's survival. Sequential rather than simultaneous use is the usual approach.
Lacticaseibacillus casei HRVD300-US + garlicAllicin and related thiosulfinates have broad antibacterial activity in vitro.
Crushed garlic generates allicin, which reacts with bacterial thiol enzymes across many species. Whether an ordinary culinary or supplemental dose reaches the colon in an active form is uncertain. Read the interaction as plausible rather than measured.
Lacticaseibacillus casei HRVD300-US + berberineBerberine has antimicrobial activity that shifts gut bacterial composition.
Berberine is poorly absorbed, so much of an oral dose stays in the gut lumen where it acts on bacterial populations. It changes community composition rather than acting selectively. A delivered culture sits in that altered environment, and timing separation is the pragmatic approach.
Lacticaseibacillus casei HRVD300-US + vitamin-d3Vitamin D receptor signalling is present in intestinal epithelium and shapes barrier and immune function there.
Intestinal epithelial cells express the vitamin D receptor, and its signalling contributes to normal tight junction protein expression. A live culture acts from the luminal side; vitamin D acts on the host cell. They approach the same barrier from opposite faces.
Who should be cautious
Talk to a doctor before taking Lacticaseibacillus casei HRVD300-US if any of these apply to you: Initial gas possible when starting. These are flags to check first, not effects Lacticaseibacillus casei HRVD300-US is known to cause.
Not medical advice. Show the label to your pharmacist.Getting Lacticaseibacillus casei HRVD300-US from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
Yakult (fermented milk)Fermented vegetablesKefir
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
Delayed-release deliveryThe dried culture is enclosed in a shell that resists gastric acid and opens at intestinal pH.Fits Products aiming to reduce acid exposure before the culture reaches the intestine.Trade-off Adds coating material and cost, and release depends on the individual's gastric emptying and intestinal pH rather than a fixed schedule.Active and formulation aid
Live culture in a fermented food matrixCells remain in the fermented milk or dairy matrix in which they were grown, with the matrix providing buffering during gastric transit.Fits Food-format products where the matrix is part of the delivery.Trade-off Requires cold chain, has a short shelf life, and the CFU count moves throughout that life rather than sitting at a label figure.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.
